Atopic dermatitis of the flexure crease of the elbow. Credit: James Heilman.

Pfizer has started a Phase III clinical programme of its product candidate PF-04965842 for the treatment of patients with moderate-to-severe atopic dermatitis (AD).

PF-04965842 is an oral, small molecule, selective inhibitor of Janus kinase 1 (JAK1), and the inhibition is reported to regulate various cytokines that are involved in pathophysiology of the condition.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Pfizer has begun the programme with the pivotal B7451012 trial that is set to be initially carried out in North America, Australia and Europe, with plans for expansion in 2018.

The randomised, double-blind, placebo-controlled, parallel-group trial will assess the safety and efficacy of 100mg and 200mg once daily PF-04965842 over 12 weeks in 375 subjects aged 12 years and above.

“By initiating this Phase III programme in atopic dermatitis, we hope to provide a new potential treatment option for people suffering with this condition.”

Pfizer Global Product Development Inflammation & Immunology chief development officer Michael Corbo said: “By initiating this Phase III programme in atopic dermatitis, we hope to provide a new potential treatment option for people suffering with this condition.

“Pfizer continues to build a leadership position in inflammation and immunology research with the advancement of this important, Pfizer-discovered investigational oral JAK1 inhibitor.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoints of the Phase III B7451012 trial are proportion of patients experiencing an improvement in Investigator Global Assessment (IGA) score, and those achieving a minimum of 75% or greater change in the Eczema Area and Severity Index (EASI) score from baseline.

After the treatment period, patients can choose to remain in a safety follow-up period of four weeks or opt for a long-term extension study (B7451015) at Week 12.